Clinical expansion Nektar is advancing lead asset rezpegaldesleukin through Phase III trials for atopic dermatitis and alopecia areata, funded by a recent 250 million public offering. Potential sales angle: provide CRO support, randomized controlled trial facilitation, and regulatory submission readiness services to accelerate timelines.

Funding momentum The company secured substantial funding to support late-stage development and manufacturing, signaling readiness for scale. Opportunities exist to offer manufacturing optimization, contract development and manufacturing organization (CDMO) partnerships, and supply chain resilience solutions.

Partnership potential Nektar emphasizes collaboration with leading pharmaceutical companies to translate research into therapies. Identify co-development, licensing, or strategic alliance opportunities, as well as data analytics collaborations to de-risk development pipelines.

Regulatory risk Multiple class action and securities-related lawsuits have affected investor confidence. Sales teams can position governance, due diligence, and investor communications services, plus risk assessment solutions for life sciences clients dealing with corporate governance and compliance.

Immunology focus With a strategic focus on autoimmune and inflammatory diseases, there is a clear opportunity to offer specialized assay development, biomarker services, and real-world evidence collection to support competitive differentiation and post-market surveillance efforts.